FWP
CTMX icon

Forefront Wealth Partners’s CytomX Therapeutics CTMX Stock Holding History

Forefront Wealth Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,109
Closed -$57.8K – 149
2025
Q3 		$57.8K Buy
+18,109
New +$40.8K 0.01% 191

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Forefront Wealth Partners's CTMX Position: Q4 2025 in Review

Forefront Wealth Partners sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 18,109 shares — an estimated $57.8K sold.

Forefront Wealth Partners first reported a position in CTMX in Q3 2025 and held it in 1 quarter. The position peaked at $57.8K in Q3 2025. 121 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

  • Forefront Wealth Partners reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Forefront Wealth Partners sold 18,109 CytomX Therapeutics shares in Q4 2025, an estimated $57.8K.
  • Forefront Wealth Partners first reported a position in CytomX Therapeutics in Q3 2025 and held it in 1 quarter.
  • Forefront Wealth Partners's CytomX Therapeutics position peaked at $57.8K in Q3 2025.
  • 121 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on Forefront Wealth Partners's 13F filing for Q4 2025, filed 6 Feb 2026.